NZ241672A - Use of rapamycin to prepare medicaments for the treatment/prevention of pulmonary inflammation in mammals - Google Patents
Use of rapamycin to prepare medicaments for the treatment/prevention of pulmonary inflammation in mammalsInfo
- Publication number
- NZ241672A NZ241672A NZ241672A NZ24167292A NZ241672A NZ 241672 A NZ241672 A NZ 241672A NZ 241672 A NZ241672 A NZ 241672A NZ 24167292 A NZ24167292 A NZ 24167292A NZ 241672 A NZ241672 A NZ 241672A
- Authority
- NZ
- New Zealand
- Prior art keywords
- rapamycin
- pulmonary inflammation
- medicament
- mammal
- treatment
- Prior art date
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims abstract description 22
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims abstract description 22
- 229960002930 sirolimus Drugs 0.000 title claims abstract description 22
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 10
- 241000124008 Mammalia Species 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 title claims description 7
- 230000002265 prevention Effects 0.000 title description 2
- 208000006673 asthma Diseases 0.000 claims abstract description 10
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 4
- 206010014561 Emphysema Diseases 0.000 claims abstract description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims abstract description 4
- 206010006451 bronchitis Diseases 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 5
- 230000004941 influx Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Liquid Crystal Substances (AREA)
- External Artificial Organs (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/659,782 US5080899A (en) | 1991-02-22 | 1991-02-22 | Method of treating pulmonary inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ241672A true NZ241672A (en) | 1997-06-24 |
Family
ID=24646823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ241672A NZ241672A (en) | 1991-02-22 | 1992-02-20 | Use of rapamycin to prepare medicaments for the treatment/prevention of pulmonary inflammation in mammals |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5080899A (pt) |
| EP (1) | EP0573584B1 (pt) |
| JP (1) | JP2673168B2 (pt) |
| KR (1) | KR100201516B1 (pt) |
| AT (1) | ATE183647T1 (pt) |
| AU (1) | AU662735B2 (pt) |
| CA (1) | CA2103571C (pt) |
| DE (1) | DE69229858T2 (pt) |
| DK (1) | DK0573584T3 (pt) |
| ES (1) | ES2135404T3 (pt) |
| GR (1) | GR3031681T3 (pt) |
| HK (1) | HK1011284A1 (pt) |
| HU (1) | HUT70146A (pt) |
| IE (1) | IE920554A1 (pt) |
| IL (1) | IL100905A (pt) |
| LV (1) | LV12400B (pt) |
| NZ (1) | NZ241672A (pt) |
| PT (1) | PT100144B (pt) |
| SG (1) | SG52403A1 (pt) |
| WO (1) | WO1992014476A1 (pt) |
| ZA (1) | ZA921211B (pt) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5358944A (en) * | 1990-09-19 | 1994-10-25 | American Home Products Corporation | Rapamycin esters for treating transplantation rejection |
| US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| US5321009A (en) * | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
| US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
| US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5286731A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5164399A (en) * | 1991-11-18 | 1992-11-17 | American Home Products Corporation | Rapamycin pyrazoles |
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5262424A (en) * | 1992-02-18 | 1993-11-16 | American Home Products Corporation | Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith |
| US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| ES2089723T3 (es) | 1992-03-27 | 1996-10-01 | American Home Prod | 29-demetoxirapamicina para inducir la inmunodepresion. |
| US5288711A (en) * | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
| US5256790A (en) * | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| CA2106034A1 (en) * | 1992-09-24 | 1994-03-25 | Ralph J. Russo | 21-norrapamycin |
| US5489680A (en) * | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5480989A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5480988A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5434260A (en) * | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| US5262423A (en) * | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
| US5260300A (en) * | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| US5349060A (en) * | 1993-01-07 | 1994-09-20 | American Home Products Corporation | Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents |
| US5252579A (en) * | 1993-02-16 | 1993-10-12 | American Home Products Corporation | Macrocyclic immunomodulators |
| US7279561B1 (en) * | 1993-04-23 | 2007-10-09 | Wyeth | Anti-rapamycin monoclonal antibodies |
| ES2176245T3 (es) | 1993-04-23 | 2002-12-01 | Wyeth Corp | Anticuerpos de ramapicinas de ciclo abierto. |
| US5504091A (en) * | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
| US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5616588A (en) * | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
| IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5516770A (en) * | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
| US5378836A (en) * | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
| US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| US5373014A (en) * | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
| US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
| US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| US5385909A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
| US5389639A (en) * | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
| US5525610A (en) * | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5463048A (en) * | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
| US5491231A (en) * | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
| US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| US5496832A (en) * | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
| US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| US5922730A (en) * | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
| IT1289815B1 (it) * | 1996-12-30 | 1998-10-16 | Sorin Biomedica Cardio Spa | Stent per angioplastica e relativo procedimento di produzione |
| EE200000253A (et) | 1997-10-22 | 2001-06-15 | Ponikau Jens | Seentevastase toimeaine kasutamine ravimite valmistamiseks, mis on ette nähtud mitteinvasiivsetest seenorganismidest tingitud haiguste raviks või vältimiseks |
| US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
| US6670355B2 (en) | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
| EP1319008B1 (en) | 2000-09-19 | 2008-10-15 | Wyeth | Water soluble rapamycin esters |
| US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
| US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
| US6923927B2 (en) * | 2000-10-03 | 2005-08-02 | Atrium Medical Corporation | Method for forming expandable polymers having drugs or agents included therewith |
| TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
| TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
| US20020198137A1 (en) * | 2001-06-01 | 2002-12-26 | Wyeth | Antineoplastic combinations |
| UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| EP1419153A1 (en) | 2001-08-22 | 2004-05-19 | Wyeth | Rapamycin dialdehydes |
| EP1419154B1 (en) | 2001-08-22 | 2005-10-05 | Wyeth | Rapamycin 29-enols |
| AU2002352726A1 (en) | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| BR0313024A (pt) | 2002-07-30 | 2005-07-12 | Wyeth Corp | Formulações parenterais contendo um hidroxiéster de rapamicina |
| RU2326654C2 (ru) * | 2002-09-17 | 2008-06-20 | Уайт | Пероральные композиции |
| AR042938A1 (es) * | 2003-02-06 | 2005-07-06 | Wyeth Corp | Uso del cci-779 en el tratamiento de la fibrosis hepatica |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| AU2004231720A1 (en) * | 2003-04-22 | 2004-11-04 | Wyeth | Antineoplastic combinations |
| US20040236410A1 (en) * | 2003-05-22 | 2004-11-25 | Atrium Medical Corp. | Polymeric body formation |
| US20040236279A1 (en) * | 2003-05-22 | 2004-11-25 | Atrium Medical Corp. | Gaseous therapeutic agent delivery |
| US20040236278A1 (en) * | 2003-05-22 | 2004-11-25 | Atrium Medical Corp. | Therapeutic agent delivery |
| US20040253185A1 (en) * | 2003-06-12 | 2004-12-16 | Atrium Medical Corp. | Medicated ink |
| US7445916B2 (en) * | 2004-04-14 | 2008-11-04 | Wyeth | Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies |
| US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| AU2005294382A1 (en) * | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
| EP1962839A4 (en) | 2005-11-14 | 2010-08-25 | Ariad Pharma Inc | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER |
| US20100081681A1 (en) * | 2006-08-16 | 2010-04-01 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| RU2491934C2 (ru) * | 2006-08-22 | 2013-09-10 | Новартис Аг | Лечение фиброзирующих нарушений |
| WO2008033956A2 (en) | 2006-09-13 | 2008-03-20 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| EP2241342A3 (en) * | 2006-11-20 | 2011-01-12 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US20080175887A1 (en) * | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
| WO2009134917A2 (en) * | 2008-04-29 | 2009-11-05 | Wyeth | Methods for treating inflammation |
| WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| CA2743491C (en) | 2008-11-11 | 2016-10-11 | Zelton Dave Sharp | Inhibition of mammalian target of rapamycin |
| AU2010233073B2 (en) * | 2009-04-10 | 2014-07-31 | Haiyan Qi | Novel anti-aging agents and methods to identify them |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| US20150290176A1 (en) | 2012-10-12 | 2015-10-15 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
| MX2016004530A (es) | 2013-10-08 | 2017-02-13 | Lam Therapeutics Inc | Rapamicina para el tratamiento de linfangioleiomiomatosis. |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| CA3206208A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| CA2939342A1 (en) | 2014-02-11 | 2015-08-20 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| PL3125875T3 (pl) | 2014-04-04 | 2023-11-20 | AI Therapeutics, Inc. | Nadający się do inhalacji preparat rapamycyny do leczenia stanów związanych z wiekiem |
| US10328045B2 (en) | 2014-09-12 | 2019-06-25 | Children's Medical Center Corporation, Inc. | Dietary emulsion formulations and methods for using the same |
| EP3209330B1 (en) | 2014-10-07 | 2022-02-23 | AI Therapeutics, Inc. | An inhalable sirolimus formulation for the treatment of pulmonary hypertension |
| WO2016066608A1 (en) * | 2014-10-28 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US5023264A (en) * | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
| AU8910891A (en) * | 1990-11-20 | 1992-06-11 | National Heart & Lung Institute, The | Treatment of lung diseases |
-
1991
- 1991-02-22 US US07/659,782 patent/US5080899A/en not_active Expired - Lifetime
-
1992
- 1992-02-10 IL IL10090592A patent/IL100905A/en not_active IP Right Cessation
- 1992-02-19 ZA ZA921211A patent/ZA921211B/xx unknown
- 1992-02-20 NZ NZ241672A patent/NZ241672A/en not_active IP Right Cessation
- 1992-02-20 PT PT100144A patent/PT100144B/pt not_active IP Right Cessation
- 1992-02-21 DK DK92907905T patent/DK0573584T3/da active
- 1992-02-21 HU HU9302376A patent/HUT70146A/hu unknown
- 1992-02-21 KR KR1019930702483A patent/KR100201516B1/ko not_active IP Right Cessation
- 1992-02-21 EP EP92907905A patent/EP0573584B1/en not_active Expired - Lifetime
- 1992-02-21 ES ES92907905T patent/ES2135404T3/es not_active Expired - Lifetime
- 1992-02-21 SG SG1996004019A patent/SG52403A1/en unknown
- 1992-02-21 DE DE69229858T patent/DE69229858T2/de not_active Expired - Fee Related
- 1992-02-21 AT AT92907905T patent/ATE183647T1/de not_active IP Right Cessation
- 1992-02-21 AU AU15356/92A patent/AU662735B2/en not_active Ceased
- 1992-02-21 JP JP4507353A patent/JP2673168B2/ja not_active Expired - Fee Related
- 1992-02-21 IE IE055492A patent/IE920554A1/en not_active IP Right Cessation
- 1992-02-21 WO PCT/US1992/001398 patent/WO1992014476A1/en active IP Right Grant
- 1992-02-21 CA CA002103571A patent/CA2103571C/en not_active Expired - Fee Related
-
1998
- 1998-11-24 HK HK98112290A patent/HK1011284A1/xx not_active IP Right Cessation
-
1999
- 1999-10-21 LV LVP-99-149A patent/LV12400B/en unknown
- 1999-10-27 GR GR990402771T patent/GR3031681T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU1535692A (en) | 1992-09-15 |
| HK1011284A1 (en) | 1999-07-09 |
| EP0573584B1 (en) | 1999-08-25 |
| IL100905A (en) | 1995-11-27 |
| LV12400A (lv) | 1999-12-20 |
| IE920554A1 (en) | 1992-08-26 |
| SG52403A1 (en) | 1998-09-28 |
| GR3031681T3 (en) | 2000-02-29 |
| ES2135404T3 (es) | 1999-11-01 |
| US5080899A (en) | 1992-01-14 |
| DE69229858T2 (de) | 1999-12-09 |
| PT100144B (pt) | 1999-06-30 |
| ZA921211B (en) | 1993-08-19 |
| EP0573584A4 (pt) | 1994-02-16 |
| LV12400B (en) | 2000-07-20 |
| CA2103571C (en) | 2003-04-29 |
| ATE183647T1 (de) | 1999-09-15 |
| WO1992014476A1 (en) | 1992-09-03 |
| JP2673168B2 (ja) | 1997-11-05 |
| KR100201516B1 (ko) | 1999-06-15 |
| DE69229858D1 (de) | 1999-09-30 |
| EP0573584A1 (en) | 1993-12-15 |
| IL100905A0 (en) | 1992-11-15 |
| KR930703000A (ko) | 1993-11-29 |
| PT100144A (pt) | 1993-08-31 |
| JPH06504790A (ja) | 1994-06-02 |
| AU662735B2 (en) | 1995-09-14 |
| CA2103571A1 (en) | 1992-08-23 |
| HUT70146A (en) | 1995-09-28 |
| DK0573584T3 (da) | 1999-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0573584B1 (en) | Method of treating pulmonary inflammation | |
| JP2810599B2 (ja) | 免疫炎症性疾患の治療用医薬組成物 | |
| AU664354B2 (en) | Treatment of organ transplantation rejection | |
| EP1628682B1 (en) | Composition comprising a pde4 inhibitor and a pde5 inhibitor for the treatment of copd | |
| AU2002363443B2 (en) | New uses for anti-malarial therapeutic agents | |
| AU2002363443A1 (en) | New uses for anti-malarial therapeutic agents | |
| EP0475411A1 (en) | Novel carbocyclic adenosine analogs useful as immunosuppressants | |
| JPH06157344A (ja) | 血管新生阻害のための医薬製剤及び血管新生阻害方法 | |
| US5605903A (en) | Carbocyclic nucleoside analogs useful as immunosuppressants | |
| CA2519357A1 (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
| CA2270373A1 (en) | Synergistic composition comprising rapamycin and calcitriol | |
| US6355639B1 (en) | Reverse prenyl compounds as immunosuppressants | |
| US20040242669A1 (en) | Method of treating deficits associated with brain injury | |
| EP0475413B1 (en) | Carbocyclic nucleoside analogs useful as immunosuppressants | |
| US3743733A (en) | Method of treating bronchial asthma | |
| IE904460A1 (en) | Pharmaceuticals | |
| JP2005225853A (ja) | アレルギー性疾患又は呼吸器系疾患の予防ないし治療剤 | |
| JP2007269671A (ja) | アレルギー性皮膚炎の予防ないし治療剤 | |
| Ziment | Chest Diseases—Important Advances in Clinical Medicine: Adverse Drug Interactions With Theophylline | |
| Harakati et al. | Granulocyte—Macrophage Colony—Stimulating Factor in Newly Diagnosed Adult Patients with Acute Lymphoblastic Leukemia Treated with Conventional Chemotherapy | |
| JPH01193222A (ja) | 生体防御能亢進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |